Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association.

Author: Agmon-LevinN, RamotY, ShamrizO, TalY, YahiaS H

Paper Details 
Original Abstract of the Article :
Belimumab, an anti-B-lymphocyte stimulator monoclonal antibody, was recently approved for the treatment of systemic lupus erythematosus. Alopecia areata is characterized by an acute immune-mediated hair loss. Herein, we report on three adult systemic lupus erythematosus patients who developed alopec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/0961203319899985

データ提供:米国国立医学図書館(NLM)

Belimumab and Alopecia Areata: A Sandstorm in the Desert of Lupus Treatment

Systemic lupus erythematosus (SLE), a chronic autoimmune disease, is like a relentless sandstorm, wreaking havoc on the body's immune system. This case report delves into a potential side effect of belimumab, a medication used to treat SLE, highlighting a potential sandstorm in the desert of lupus treatment. The report examines the development of alopecia areata, a condition characterized by hair loss, in three adult SLE patients who were treated with belimumab.

Navigating the Shifting Sands of Lupus Treatment

The report's findings raise concerns about the potential for belimumab to trigger alopecia areata in some SLE patients. It's like navigating a desert where the sand dunes are constantly shifting, requiring careful observation and a flexible approach. The report suggests that close monitoring for hair loss is crucial for patients receiving belimumab, and discontinuation of the medication might be necessary in cases where alopecia areata develops.

Staying Alert in the Desert of Lupus Treatment

The report emphasizes the importance of vigilance and open communication between patients and their healthcare providers. It's essential for patients to be aware of the potential side effects associated with their medications, allowing for prompt detection and management of any unexpected changes. By remaining vigilant, patients can better navigate the desert of lupus treatment, seeking timely intervention when necessary.

Dr. Camel's Conclusion

The desert of lupus treatment is full of challenges, and this case report highlights a potential sandstorm in the form of alopecia areata. While belimumab offers significant benefits for many SLE patients, it's crucial to be aware of potential side effects. Close monitoring and open communication between patients and healthcare providers are essential for navigating this complex terrain, ensuring timely intervention when necessary.

Date :
  1. Date Completed 2020-12-08
  2. Date Revised 2020-12-14
Further Info :

Pubmed ID

31924144

DOI: Digital Object Identifier

10.1177/0961203319899985

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.